Posted by Michael Wonder on 14 Jan 2020
PTC Therapeutics provides corporate update
13 January 2020 - PTC-AADC MAA submitted; BLA now expected to be submitted in 2Q 2020.
PTC has submitted a marketing authorisation application for the potential approval of a gene therapy treatment, PTC-AADC, for AADC deficiency with the EMA.
PTC expects the Committee for Medicinal Products for Human Use opinion in 2H 2020.
